Revvity, Inc. , today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against ...
News-Medical.Net on MSN4d
Updates on influenza vaccine strain recommended by WHO (2025-2026 northern hemisphere)To maintain vaccine efficacy, WHO regularly updates influenza vaccine strains based on global epidemiological, virological, ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
The Business Research Company The Business Research Company's Vitamin Biomarkers Global Market Report 2025 – Market Size, Trends, And Forec ...
StudyFinds on MSN13d
Breakthrough blood test could transform ALS diagnosis, careFind out about the new ALS blood test that offers accurate diagnosis and could replace traditional invasive testing methods.
The Nation UAE on MSN1d
Panic in Taunsa Sharif after 50 children test HIV/AIDS positiveIn an unprecedented crisis, a small town called Taunsa Sharif, located in South Punjab, is grappling with an alarming outbreak of HIV/AIDS among minor children aged from nine months to 10 years, with ...
AZoLifeSciences on MSN2d
Bispecific antibodies for SARS-CoV-2 variant neutralizationBispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...
Your IP is registered with the company mentioned above and provides access to Life Science Sweden.
The firm's Anti-Measles Virus ELISA 2.0 (IgG) is used with dried blood spot samples to identify infections and determine patients' immune status.
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback